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analyses.  Results: The optimal cut-off score for the ACE-R for 
detecting MCI, AD, and FTLD was 86/87, 82/83 and 83/84, re-
spectively. ACE-R was superior to MMSE only in the detec -
 tion of patients with FTLD [area under the curve (AUC): 0.97 
vs. 0.92], whilst the accuracy of the two instruments did not 
differ in identifying MCI and AD. The ratio of the scores of the 
memory ACE-R subtest to verbal fluency subtest contributed 
significantly to the discrimination between AD and FTLD 
(optimal cut-off score: 2.30/2.31, AUC: 0.77), whereas the 
MMSE and ACE-R total scores did not.  Conclusion: The Ger-
man ACE-R is superior to the most commonly employed 
MMSE in detecting mild dementia in FTLD and in the differ-
ential diagnosis between AD and FTLD. Thus it might serve 
as a valuable instrument as part of a comprehensive diag-
nostic workup in specialist centres/clinics contributing to
the diagnosis and differential diagnosis of the cause of de-
mentia.  Copyright © 2010 S. Karger AG, Basel
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 Abstract
 Background/Aims: The diagnostic accuracy of the German 
version of the revised Addenbrooke’s Cognitive Examination 
(ACE-R) in identifying mild cognitive impairment (MCI), mild 
dementia in Alzheimer’s disease (AD) and mild dementia in 
frontotemporal lobar degeneration (FTLD) in comparison 
with the conventional Mini Mental State Examination (MMSE) 
was assessed.  Methods: The study encompasses 76 cogni-
tively healthy elderly individuals, 75 patients with MCI, 56 
with AD and 22 with FTLD. ACE-R and MMSE were validated 
against an expert diagnosis based on a comprehensive diag-
nostic procedure. Statistical analysis was performed using 
the receiver operating characteristic method and regression 
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 Introduction
 Due to the rapidly ageing population in the Western 
world, the incidence of age-related disorders such as de-
mentia is increasing substantially and dramatically. De-
mentia is predicted to become the largest health care 
challenge in modern history because of its medical, social 
and philosophical implications  [1] . An early diagnosis of 
dementia appears to be of great importance in order to 
institute appropriate medical and social interventions. 
Alzheimer’s disease (AD) is the most common cause of 
dementia  [2] , and frontotemporal lobar degeneration 
(FTLD) is the second most common presenile cause of 
neurodegenerative dementia  [3] . Depending on its cause, 
the clinical phenotypes are quite distinct at the stage of 
mild dementia. Patients with mild dementia in AD, for 
instance, manifest memory deficits, make repetitive 
statements, get lost while driving and have poor judg-
ment, whereas subjects with mild dementia in FTLD pri-
marily present with alterations of speech (language vari-
ant of FTLD) or with behavioural disturbances such as 
disinhibition and lack of social awareness (behavioural 
variant of FTLD)  [2] .
 In most cases, the diagnosis of dementia is established 
by assessing cognitive deficits and their impact on the 
activities of daily living. Neuropsychological instruments 
enable clinicians to gather evidence of cognitive impair-
ment, help them to detect dementia and to make a differ-
ential diagnosis. In the light of the long duration (around 
1–4 h) of extensive neuropsychological testing, which 
limits its utility in routine dementia diagnostic workup, 
there is a demand for screening tests  [4] . Ideally, such tests 
are sensitive and specific, reliable and valid, quickly ad-
ministered, easily scored, and capture a broad range of 
cognitive abilities across various levels of difficulty, thus 
being efficient, not only in identifying mild dementia in 
AD, but also other forms of dementia  [5, 6] .
 Many screening tools for dementia which are available 
in German have been criticized for several shortcomings. 
For instance, the 7-Minute Screen is difficult to score and 
to interpret  [7] . The DemTect  [8] does not assess visuo-
spatial ability, known to be closely associated with func-
tional abilities  [9] . The 3MS has been validated in Ger-
many only for the identification of patients with early AD 
but not with mild cognitive impairment (MCI) or with 
dementias of other aetiologies  [10] . The Mini Mental State 
Examination (MMSE)  [11] is currently the most widely 
used measure of cognitive performance in Germany and 
in many other countries. It has been shown to be a useful 
tool for distinguishing people with dementia from cogni-
tively healthy individuals and to achieve an acceptable 
sensitivity and specificity in detecting dementia in clini-
cal samples  [12–14] . However, several weaknesses of the 
MMSE have been repeatedly demonstrated, including 
small number of items, low level of task difficulty and 
likelihood of ceiling effects, narrow range of cognitive 
domains assessed (including overrepresentation of orien-
tation, underrepresentation of memory tasks and absence 
of tasks measuring executive function), limited range of 
possible scores for individual items  [6] and low sensitiv-
ity for the detection of patients with MCI  [15, 16] . Fur-
thermore, the diagnostic accuracy of the MMSE depends 
on the patient’s age, education level, and ethnicity  [15] .
 Drawing on extensive clinical and research expertise 
with cognitive tests, Hodges and colleagues developed 
the Addenbrooke’s Cognitive Examination test battery 
 [17] and a modified version of it. Changes were intro-
duced into the revised version of Addenbrooke’s Cogni-
tive Examination (ACE-R)  [18] in order to avoid ceiling 
effects and to provide a more balanced contribution of 
the component tests to the final score. Administration of 
the ACE-R requires approximately 15 min and is easy to 
score and to interpret. It incorporates the MMSE, but 
elaborates on memory, language and visuospatial compo-
nents, and adds component tests of verbal fluency. The 
memory component test assesses semantic and episodic 
memory. In addition to recall of 3 items taken from the 
MMSE, there is a name and address recall and recogni-
tion test for assessing episodic memory. Semantic mem-
ory is tested with 4 questions concerning general knowl-
edge. The language section comprises the naming of 12 
line drawings of intermediate and low familiarity, seman-
tic comprehension, sentence comprehension, repetition 
of words and phrases, reading of irregular words, and 
writing a sentence. Executive functions are tested by let-
ter fluency (generating words beginning with the letter P 
in 1 min) and category fluency (generating names of an-
imals in 1 min). Visuospatial testing includes the copying 
of overlapping pentagons (from the MMSE) and of a wire 
cube, the drawing of a clock face, dot counting and iden-
tifying fragmented letters  [18] .
 The maximum ACE-R score of 100 points is composed 
of 5 component test scores: orientation and attention (18 
points), memory (26 points), verbal fluency (14 points), 
language (26 points) and visuospatial ability (16 points) 
 [18] . The original validation study, which was conducted 
at Addenbrooke’s Hospital, UK, included 241 partici-
pants. It suggested an optimal cut-off score of 88 points 
for identifying dementia, which was associated with high 
sensitivity (94%) and specificity (89%)  [18] .
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 The aim of the present study was to investigate the 
ability of the German version of the ACE-R to detect pa-
tients with MCI, mild dementia in AD, and mild demen-
tia in FTLD, and to compare its diagnostic accuracy with 
that of the MMSE. The ACE-R and MMSE were validated 
against the clinical diagnosis based on a comprehensive 
diagnostic workup.
 Methods, Study Sample and Design
 We translated and modified the instrument with advice from 
the authors of the original ACE-R. The modifications concerned 
the name and address recall and recognition tests, the semantic 
memory test and the repetition test. Based on the original criteria, 
the German addresses were chosen from common street names 
and from less well-known towns in order to preclude natural as-
sociations (e.g. Frauenstrasse 24, Spremberg, Brandenburg). In 
the semantic memory test, we replaced ‘the current prime minis-
ter’ and ‘the woman who was prime minister’ by ‘the name of the 
current chancellor’ and ‘the name of the previous chancellor’. The 
words in the repetition test (‘Hippopotamus, Exzentrizität, Un-
verhältnismässigkeit, Verantwortungslosigkeit’ and ‘oberhalb, 
ausserhalb und unterhalb’) were selected according to the criteria 
used in the original English version: length, frequency and diffi-
culty to articulate. A bilingual researcher at the University of 
Cambridge performed a back translation into English. Compari-
son of the original English version with the back translation 
showed that the new version was similar to the original one except 
for the modified items  [19] . The scoring system was not changed. 
Like the English original, the German ACE-R can be adminis-
tered in approximately 15 min.
 The validation study was carried out at 3 university memory 
clinics, located in Erlangen and in Munich, Germany. The exam-
ination of the participants included a history from the patient and 
from an informant, medical, neurological and psychiatric exami-
nation, laboratory screening, brain imaging (MRI or CT) and a 
neuropsychological examination based on the German version of 
the Consortium to Establish a Registry for Alzheimer’s Disease 
Neuropsychological Assessment Battery (CERAD-NAB)  [20] , 
which incorporates the MMSE. The additional neuropsychologi-
cal examination comprised a flexible battery (Trail Making Test 
 [21] , Bayer Activities of Daily Living Scale  [22] , and Neuropsychi-
atric Inventory  [23] ), the components of which varied according 
to the aims of the neuropsychological assessment of each patient 
as defined by the clinician.
 The participants were German-speaking and had adequate vi-
sion and hearing, although many wore glasses and some required 
a hearing aid. The ACE-R was administered after the clinical and 
neuropsychological examination. The components of the ACE-R 
that are identical to those of the MMSE were not administered 
twice in order to preclude learning effects. The clinical diagnoses 
were established independent of the performance of participants 
on the ACE-R. The diagnosis of dementia and the assessment of 
its overall severity were based on the criteria of the ICD-10 clas-
sification system  [24] . AD diagnosis was based on the criteria of 
the National Institute of Neurological and Communicative Dis-
orders and Stroke-Alzheimer’s Disease and Related Disorders As-
sociation (NINCDS-ADRDA) for probable AD  [25] . The diagno-
sis of FTLD was established according to the revised Lund-Man-
chester criteria  [26] . To ensure that patients with dementia had not 
crossed the threshold to moderate dementia, patients with a score 
below 15 points on the MMSE were excluded from the study. This 
score has been found to discriminate mild from moderate demen-
tia  [27] . MMSE staging has been proven to be an effective clinical 
instrument for tracking the stages of dementia  [27] . The diagnosis 
of MCI followed the revised consensus criteria of the Internation-
al Working Group on Mild Cognitive Impairment  [28] . The cog-
nitively healthy controls were recruited among spouses and 
friends of patients of the 3 memory clinics. They had normal cog-
nitive performance according to the MMSE, were independent in 
their activities of daily living and did not have any memory com-
plaints. Subjects with serious medical, psychiatric or neurological 
disorders which could affect cognitive functioning (e.g. major
depression, schizophrenia, seizure disorder, head injury) or with 
a score on the MMSE of  ! 28 were excluded.
 The study protocol was approved by the Ethics Committee of 
the Medical Faculty of the Friedrich-Alexander-Universität Er-
langen-Nürnberg, Germany.
 Statistical Analyses
 Statistical analyses were implemented in PASW Statistics 17.0 
for Windows (SPSS, Chicago, Ill., USA); p values of less than 0.05 
were considered to indicate statistical significance.
 Differences with regard to demographic variables, MMSE 
scores and component and total scores of the ACE-R among cog-
nitively healthy controls and patients with MCI, AD and FTLD 
were tested using one-way analysis of variance. Pairwise compar-
isons were performed using Bonferroni’s test.   2  tests were em-
ployed for nominal (categorical) data. If differences attained sta-
tistical significance, a linear regression analysis was carried out 
to investigate possible associations between the demographic 
variable which varied significantly across the groups and the par-
ticipants’ performance in the ACE-R.
 The first step of the analysis of the utility of the ACE-R and the 
MMSE encompassed a logistic regression analysis, assessing the 
extent to which ACE-R and MMSE scores predict the clinical di-
agnosis. ACE-R and MMSE scores were fed as explanatory vari-
ables and the clinical diagnosis as outcome variable. If the utility 
analysis revealed significantly higher accuracy of the ACE-R in 
discriminating between cognitively healthy controls and patients 
in comparison with the MMSE, a logistic regression analysis was 
carried out to assess which ACE-R component tests contributed 
to the higher accuracy of the instrument. The second step com-
prised the performance of a receiver operating characteristic 
(ROC) curve analysis. The area under the curve (AUC) was used 
as a measure of the accuracy of the ACE-R and MMSE to distin-
guish between the groups of participants. AUC values of less than 
1.0 (perfect test) refer to excellent ( 1 0.9), good ( 1 0.8), fair ( 1 0.7) 
and poor ( 1 0.6) accuracy  [29] . Differences between AUCs were 
assessed with the StAR software for the statistical comparison
of ROC curves  [30] . The ROC was also used to select an optimal 
cut-off value below which an individual has a very high chance
of suffering from the aforementioned clinical syndromes and
disorders.
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 Results
 The present study refers to 56 patients with mild de-
mentia in AD, 75 patients with MCI, 22 patients with 
mild dementia in FTLD (14 with the frontal variant of 
FTLD and 8 with the language variant) and 76 cognitive-
ly healthy controls. Demographic data and MMSE and 
ACE-R total and component scores of the four groups of 
individuals are presented in  table 1 . There were no statis-
tical differences regarding age and years of education be-
tween the control group and the patient groups. The MCI 
group included significantly fewer female participants 
than the healthy controls (Fisher’s exact test, p = 0.015). 
The linear regression analysis, using the ACE-R scores as 
dependent variable and diagnosis (MCI vs. no cognitive 
deficits) and gender distribution as independent factors 
(F = 28,523, p  ! 0.0001), did not reveal a significant im-
pact of gender distribution on ACE-R performance (stan-
dardized partial regression coefficient of clinical diagno-
sis = –0.03, p = 0.72), whereas the impact of the clinical 
diagnosis was significant (standardized partial regres-
sion coefficient of clinical diagnosis = –0.523, p  ! 0.0001). 
No significant differences were detected between the 
FTLD and the AD groups with regard to age, education 
and gender.
 Concerning the performance on ACE-R component 
tests, patients with MCI had significantly lower scores on 
all ACE-R component tests than cognitively healthy con-
trols except for attention/orientation and visuospatial 
ability (memory p  ! 0.0001, verbal fluency p  ! 0.0001, 
language p = 0.016). They also had lower total scores on 
MMSE and on ACE-R in comparison with healthy con-
trols (p  ! 0.0001 for both tests). Patients with AD and 
FTLD performed worse than healthy controls on all 
ACE-R component tests, as well as on the MMSE and the 
ACE-R total score (all p  ! 0.0001). Regarding differences 
in the performance between AD and FTLD patients, the 
former scored higher on the verbal fluency ACE-R com-
ponent test (p = 0.044) and lower on ACE-R memory 
tasks (p = 0.008) compared to the latter. However, there 
were no differences between the two groups concerning 
the ACE-R total score and the rest of the cognitive do-
mains assessed with the ACE-R.
 Distinction between Patients with MCI and 
Cognitively Healthy Controls
 The logistic regression analysis (likelihood ratio   2  = 
73.74, p  ! 0.0001) with clinical diagnosis (MCI vs. healthy 
controls) as dependent variable and ACE-R (regression 
coefficient = –0.16, p  ! 0.0001) and MMSE scores (regres-
sion coefficient = –0.87, p  ! 0.0001) as independent fac-
tors revealed that both instruments can significantly con-
tribute to the discrimination between MCI and cogni-
tively healthy controls. The results of the ROC analyses, 
which showed that the AUC of the ACE-R was slightly 
and not significantly (p  1 0.05) larger than that of the 
MMSE, are displayed in  figure 1 and  table 2 .
 Distinction between Patients with Mild Dementia in 
AD and Cognitively Healthy Controls
 The ACE-R contributed and the MMSE strongly tend-
ed to contribute significantly to the discrimination be-
 Table 1.  Description of study sample, and component and composite mean scores  8 SD on the ACE-R and on the MMSE
 Group variable   Cognitively 
 healthy controls 
 MCI  Mild dementia
 in AD 
 Mild dementia
 in FTLD 
 Number of subjects 76 75 56 22 
 Age, years   69.64 8 7.53  67.83 8 8.01  72.00 8 8.18  69.64 8 6.18 
 Gender:female ratio, % 61.5 40.0 a 64.2 40.9 
 Education, years   11.78 8 2.51  12.00 8 3.27  11.02 8 2.63  11.70 8 3.52 
 MMSE score   29.09 8 0.73  27.29 8 1.82 a  23.21 8 3.25 a    23.45 8 5.54 a   
 ACE-R, total score   90.37 8 4.99  81.34 8 9.09 a    64.80 8 11.32 a    64.50 8 17.82 a 
 Orientation and attention ACE-R component test  17.95 8 0.23  17.31 8 0.97  14.30 8 3.07 a  14.91 8 3.74 a 
 Memory ACE-R component test  22.45 8 2.70  18.04 8 4.75 a    10.46 8 5.26 a  14.14 8 6.24 a, b 
 Verbal fluency ACE-R component test 9.82 8 2.06 7.99 8 2.56 a   6.21 8 3.60 a 4.36 8 2.68 a, b 
 Language ACE-R component test  25.13 8 1.25  23.53 8 2.30 a    21.23 8 4.24 a  19.18 8 6.43 a   
 Visuospatial ability ACE-R component test  15.05 8 1.53  14.65 8 1.75  12.59 8 2.98 a  11.41 8 3.50 a   
 a  Significant difference from cognitively healthy controls, p < 0.05.  b  Significant difference from AD patients, p < 0.05. 
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tween AD and cognitively healthy controls according to 
the logistic regression analysis (likelihood ratio   2  = 
167.68, p  ! 0.0001) with clinical diagnosis (AD vs. healthy 
controls) as dependent variable and ACE-R (regression 
coefficient = –0.44, p = 0.02) and MMSE scores (regres-
sion coefficient = –6.48, p = 0.05) as independent factors. 
The AUCs did not differ according to the ROC analyses 
( table 2 ;  fig. 2 ).
 Distinction between Patients with Mild Dementia in 
FTLD and Cognitively Healthy Controls
 The logistic regression analysis (likelihood ratio   2  = 
72.28, p  ! 0.0001) with clinical diagnosis (FTLD vs. 
healthy controls) as dependent variable and ACE-R (re-
gression coefficient = –0.28, p = 0.01) and MMSE scores 
(regression coefficient = –0.85, p = 0.19) as independent 
factors revealed that only the ACE-R significantly con-
tributes to the discrimination between FTLD and cogni-
tively healthy controls. Due to this significant difference 
between the accuracy of the two instruments, a further 
logistic regression analysis (likelihood ratio   2  = 80.8,
p  ! 0.0001) was carried out to assess which ACE-R com-
ponent tests contribute significantly to the discrimina-
tion between FTLD and cognitively healthy controls. The 
ACE-R component tests and the clinical diagnosis (FTLD 
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 Fig. 1. ACE-R and MMSE ROC for the detection of patients with 
MCI.
 
 Fig. 2. ACE-R and MMSE ROC for the detection of patients with 
mild dementia in AD.
 
 Table 2.  Optimal cut-off scores and diagnostic utility of the ACE-
R and the MMSE for identifying MCI, mild dementia in AD and 
mild dementia in FTLD
 ACE-R  MMSE 
 Distinction between patients with MCI and cognitively healthy 
controls 
 Optimal cut-off score  86/87  28/29 
 Sensitivity 0.82 0.78 
 Specificity 0.68 0.73 
 Area under the curve 0.83 0.81 
 Distinction between patients with mild dementia in AD and
 cognitively healthy controls 
 Optimal cut-off score  82/83  27/28 
 Sensitivity 0.92 1.00 
 Specificity 0.96 0.93 
 Area under the curve 0.99 0.99 
 Distinction between patients with mild dementia in FTLD and 
cognitively healthy controls 
 Optimal cut-off score  83/84  27/28 
 Sensitivity 0.88 0.73 
 Specificity 0.96 0.97 
 Area under the curve 0.97 0.92 
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vs. healthy controls) were entered into the model as inde-
pendent and dependent variables, respectively. The ACE-
R verbal fluency component test (regression coefficient = 
–0.73, p = 0.01) and the language component test (regres-
sion coefficient = –0.92, p = 0.02) were significantly as-
sociated with the clinical diagnosis, whereas the ACE-R 
memory component test (regression coefficient = –0.24, 
p = 0.17), the visuospatial component test (regression co-
efficient = 0.38, p = 0.37) and the attention-orientation 
component test (regression coefficient = –3.31, p = 0.07) 
were not. The AUC of the ACE-R was larger than that of 
the MMSE (0.97 vs. 0.92), though the difference did not 
attain statistical significance (p  1 0.05) ( table 2 ;  fig. 3 ).
 Regarding the utility of the ACE-R in discriminating 
between healthy controls and patients suffering from the 
frontal variant of FTLD, the results of the regression and 
ROC analyses did not deviate from the aforementioned 
findings concerning all FTLD patients. In short, the pa-
tients with the frontal variant of FTLD did not differ from 
healthy controls in demographic characteristics. Only 
the ACE-R (regression coefficient = –0.27, p = 0.02) pre-
dicted the clinical diagnosis with highly significant ac-
curacy and not the MMSE (regression coefficient = –0.77, 
p = 0.28) according to the regression analysis (likelihood 
ratio   2  = 54.27, p  ! 0.0001). The ROC also revealed a su-
periority of the ACE-R to MMSE in discriminating be-
tween healthy controls and patients with the frontal vari-
ant of FTLD (AUC: 0.96 vs. 0.92). Such analyses were
not performed for patients with the language variant of 
FTLD due to the limited subsample size.
 Distinction between Patients with Mild Dementia in 
FTLD and Patients with Mild Dementia in AD
 The memory to verbal fluency (M/VF) ratio was cal-
culated since the FTLD and AD groups differed signifi-
cantly with regard to memory and verbal fluency ACE-R 
subtest scores. Its value was significantly higher in the 
FTLD group than in the AD group [mean (SD): 4.13 
(2.77) vs. 2.18 (2.07), t = –2.87, p = 0.01]. The logistic re-
gression analysis (likelihood ratio   2  = 9.91, p = 0.02) with 
clinical diagnosis (FTLD vs. AD) as dependent variable 
and ACE-R M/VF ratio (regression coefficient = 0.35, p = 
0.01), ACE-R total score (regression coefficient = 0.03,
p = 0.35) and MMSE score (regression coefficient = –0.06, 
p = 0.61) as independent factors revealed that only the 
ACE-R M/VF ratio is a significant predictor of the clini-
cal diagnosis. According to the ROC, the ACE-R M/VF 
ratio (AUC = 0.77, optimal cut-off score = 2.30/2.31, sen-
sitivity = 0.70, specificity = 0.76) was shown to be more 
useful in the distinction between FTLD and AD with fair 
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 Fig. 3. ACE-R and MMSE ROC for the detection of patients with 
mild dementia in FTLD.
 
 Fig. 4. ACE-R M/VF ratio, ACE-R and MMSE ROC for the dis-
tinction between patients with mild dementia in FTLD and pa-
tients with mild dementia in AD. 
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accuracy than the ACE-R total score (AUC = 0.60) or the 
MMSE (AUC = 0.64) ( fig. 4 ), the accuracy of which was 
poor. The AUCs of the MMSE and the ACE-R total score 
were not significantly different from 0.5 (p  1 0.05), a val-
ue indicating that the results are not better than chance 
at predicting the presence of FTLD or AD.
 Discussion
 The role of neurocognitive examination is central in 
the diagnostic workup of cognitive impairment in ageing. 
The present study was performed to evaluate the accu-
racy of the German version of the ACE-R in the distinc-
tion between MCI, mild dementia in AD, FTLD, and cog-
nition in normal ageing.
 The ACE-R was not found to be more accurate than 
the MMSE in distinguishing patients with MCI from 
cognitively healthy controls. The high values of the AUCs 
for both tests (0.83 for the ACE-R and 0.81 for the MMSE) 
and the significant association between ACE-R and 
MMSE scores (both p  ! 0.0001) with the clinical diagno-
sis according to the regression analysis, implying a good 
accuracy, should be interpreted with caution, since the 
MMSE has not been proven to be effective in identifying 
mild cognitive deficits  [15, 16] . These findings possibly 
reflect a common problem in the recruitment of elderly 
control subjects. Such volunteers typically represent a se-
lected group of very healthy and highly functioning el-
derly, differing from the general elderly population, and 
especially from the elderly individuals referred for de-
mentia evaluation  [10, 31–33] . Studies of distinct cogni-
tively impaired and cognitively normal samples maxi-
mize test performance characteristics  [34] . Thus, from 
the clinician’s perspective, emphasis should be placed on 
the absence of ACE-R superiority to the MMSE in distin-
guishing healthy controls from patients with MCI.
 According to our findings, both the German ACE-R 
and the MMSE have very high accuracy in detecting mild 
dementia in AD according to the ROC analysis (both 
AUCs = 0.99). These extremely high levels of accuracy 
should, however, be treated with caution, owing to the 
findings of a recent review study which did not point out 
such a high utility of the MMSE in detecting patients with 
dementia in AD  [35] . The ACE-R scores were significant-
ly associated with the clinical diagnosis according to the 
logistic regression analysis (p = 0.02). Since the ACE-R 
encompasses features of learning materials over a series 
of trials and a delayed recall component, it was expected 
to be superior to the MMSE in identifying mild dementia 
in AD. Nevertheless, the shorter MMSE with a p value of 
0.05 was shown to tend to predict the clinical diagnosis 
with high accuracy and to be equally effective in the de-
tection of patients with mild dementia in AD as the lon-
ger ACE-R according to the ROC analysis. Our findings 
are in line with the observation that no brief cognitive test 
has yet been found to be clinically superior over others in 
identifying AD  [4] . In the light of the current short con-
sultation times, the equal effectiveness of the two instru-
ments to detect mild dementia in AD may act as a disin-
centive to clinical usage of the ACE-R.
 ACE-R was found superior to MMSE in detecting mild 
dementia in FTLD according to the regression and ROC 
analyses. Though the AUCs of the two instruments dif-
fered (AUC = 0.97 vs. 0.92), the difference did not reach 
statistical significance. The absence of statistical signifi-
cance can be explained by the relatively limited sample 
size of the FTLD group. The superiority of the ACE-R can 
be attributed to its component tests that assess cognitive 
domains affected by FTLD (i.e. executive function, verbal 
fluency)  [36] but are not covered by the MMSE. The re-
gression analysis revealed a highly significant association 
between the clinical diagnosis and the scores of the verbal 
fluency ACE-R component test (p = 0.01) and the lan-
guage component test (p = 0.02), which are not or only to 
a limited extent assessed by the MMSE.
 The ACE-R assesses a broad range of cognitive abili-
ties and provides a wide profile of cognitive functions/
dysfunctions. It contributes to drawing a differentiated 
picture of cognitive deficits with the objective of support-
ing diagnosis and differential diagnosis. In the present 
study, the comparison of the AD and the FTLD groups 
on the ACE-R component tests revealed differences in 
memory and verbal fluency performance. AD patients 
performed better in verbal fluency tasks, whereas the 
FTLD patients’ performance in memory tasks was sig-
nificantly higher. These observations are concordant 
with the discrepancies of the profiles of cognitive impair-
ment in these two clinical entities that are highlighted in 
the literature. For similar levels of overall cognitive de-
cline, FTLD patients have a relative preservation of mem-
ory and greater deficits in frontal functioning than AD 
patients  [36, 37] . Calculating the ACE-R M/VL ratio fur-
ther supports with fair accuracy (AUC = 0.77) the differ-
entiation between AD and FTLD.
 The German ACE-R was found to detect mild demen-
tia in FTLD more effectively and to differentiate, with the 
ACE-R M/VF ratio, between FTLD and AD patients sig-
nificantly better than the MMSE, whilst the accuracy of 
the two instruments in detecting MCI and mild dementia 
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in AD did not differ. Since ACE-R takes around 15 min 
to perform, whereas administering the MMSE lasts only 
approximately 8 min  [38] , the thorny question is posed 
about the clinical and diagnostic concept in terms of 
which the ACE-R could be most appropriately deployed. 
Measuring a broad range of cognitive abilities and com-
prising tasks and questions of variable difficulty, the 
ACE-R provides an objective and differentiated global 
profile of cognitive performance. This could serve in spe-
cialist centres/clinics as an invaluable instrument in a 
comprehensive diagnostic workup which also encom-
passes clinical, behavioural and functional features sup-
plemented by an informant report and neuroimaging 
 [39] .
 Our study has several limitations. The participants 
were recruited at university centres. Applicability and re-
liability of the ACE-R in community samples require fur-
ther investigation. The evaluation was confined to pa-
tients with MCI, AD and FTLD. Hence, we were not in 
the position to assess the effectiveness of the ACE-R in 
detecting other forms of dementia, such as dementia with 
Lewy bodies or vascular dementia. The reproducibility 
and repeatability of the ACE-R were not evaluated in this 
study, but as the ACE-R assesses cognitive functions in a 
well-standardized and objective manner, the rater-relat-
ed bias is likely to be low. The statistics of positive and 
negative predictive values were not calculated, because 
the groups of patients and healthy controls were recruited 
independently and not from a population, as well as due 
to the fact that these values cannot be compared between 
different diagnostic tests such as the ACE-R and the 
MMSE  [40] . Furthermore, the clinical diagnosis, which 
was based on a comprehensive diagnostic procedure and 
on international diagnostic criteria, was used as the ulti-
mate gold standard. In spite of the high validity of the 
diagnostic criteria, the clinical diagnoses are not always 
confirmed at autopsy  [41] . Thus, the possibly erroneous 
clinical assessments should also be taken into account. 
The validity of the ACE-R could therefore be lower than 
our results suggest.
 The diagnosis and differential diagnosis of dementia 
remain a clinically integrated process, with neurocogni-
tive testing providing only supportive evidence. The 
ACE-R, a brief and easily administered bedside test, as-
sesses a broad range of cognitive abilities, provides a dif-
ferentiated objective picture of cognitive impairment and 
detects patients with mild dementia in FTLD with higher 
accuracy than the common MMSE. It could emerge as a 
valid screening instrument that supports clinical and dif-
ferential diagnosis of dementia, in terms of the clinical 
and diagnostic concept of specialist centres/clinics.
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